MCID: GLL022
MIFTS: 62

Guillain-Barre Syndrome malady

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Guillain-Barre Syndrome

About this section

Aliases & Descriptions for Guillain-Barre Syndrome:

Name: Guillain-Barre Syndrome 10 45 23 47 12 36 35 65
Acute Inflammatory Polyneuropathy 45 23 51
Guillain-Barré Syndrome 45 23 46
Gbs 45 23 2
Acute Inflammatory Demyelinating Polyradiculoneuropathy 45 51
Acute Inflammatory Demyelinating Polyneuropathy 45 65
Fisher Syndrome 23 46
Guillain-Barré Syndrome, Acute Inflammatory Demyelinating Polyradiculoneuropathic Form 51
Gbs, Acute Inflammatory Demyelinating Polyradiculoneuropathic Form 51
Acute Idiopathic Demyelinating Polyneuropathy 51
Acute Autoimmune Peripheral Neuropathy 45
Landry-Guillain-Barre-Strohl Syndrome 45
Acute Immune-Mediated Polyneuropathy 45
Acute Postinfectious Polyneuropathy 10
Acute Infective Polyneuritis Nos 10
 
Guillain-Barré-Strohl Syndrome 45
Group B Streptococcal Infection 65
Landry-Guillain-Barre Syndrome 23
Acute Inflammatory Neuropathy 45
Acute Infectious Polyneuritis 23
Landry's Ascending Paralysis 45
Acute Infective Polyneuritis 10
Post-Infectious Polyneuritis 10
Acute Autoimmune Neuropathy 65
Post-Infective Polyneuritis 45
Postinfectious Polyneuritis 10
Acute Inf. Polyneuritis 10
Miller Fisher Syndrome 65
Infectious Neuronitis 10
Aidp 51

Characteristics:

Orphanet epidemiological data:

51
acute inflammatory polyneuropathy:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age

Classifications:



External Ids:

Disease Ontology10 DOID:12842
ICD1027 G61.0
ICD9CM29 357.0
MeSH36 D020275
NCIt42 C26790
Orphanet51 98916
ICD10 via Orphanet28 G61.0
UMLS65 C0018378, C1963929, C3542501 C2020625, more

Summaries for Guillain-Barre Syndrome

About this section
NIH Rare Diseases:45 Guillain-barré syndrome is a rare disorder in which the body's immune system attacks part of the peripheral nervous system. symptoms include muscle weakness, numbness, and tingling sensations, which can increase in intensity until the muscles cannot be used at all. usually guillain-barré syndrome occurs a few days or weeks after symptoms of a viral infection. occasionally, surgery or vaccinations will trigger the syndrome. it remains unclear why only some people develop guillain-barré syndrome but there may be a genetic predisposition in some cases. diagnosed patients should be admitted to a hospital for early treatment. there is no cure for guillain-barré syndrome, but treatments such as plasma exchange (plasmapheresis) and high dose immunoglobulins may reduce the severity and duration of symptoms. recovery can take as little as a few days to as long as a few years. about 30% of those with guillain-barré syndrome have residual weakness. a small number may suffer a relapse many years after the initial attack. last updated: 1/16/2016

MalaCards based summary: Guillain-Barre Syndrome, also known as acute inflammatory polyneuropathy, is related to neuropathy, inflammatory demyelinating and demyelinating polyneuropathy, and has symptoms including neuralgia, ophthalmoplegia and cerebellar ataxia. An important gene associated with Guillain-Barre Syndrome is PMP22 (Peripheral Myelin Protein 22), and among its related pathways are Canonical NF-kappaB pathway and Neural Crest Differentiation. The drug immunoglobulins, intravenous has been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related mouse phenotypes are reproductive system and muscle.

Disease Ontology:10 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system.

MedlinePlus:35 Guillain-barre syndrome is a rare disorder that causes your immune system to attack your peripheral nervous system (pns). the pns nerves connect your brain and spinal cord with the rest of your body. damage to these nerves makes it hard for them to transmit signals. as a result, your muscles have trouble responding to your brain. no one knows what causes the syndrome. sometimes it is triggered by an infection, surgery, or a vaccination. the first symptom is usually weakness or a tingling feeling in your legs. the feeling can spread to your upper body. in severe cases, you become almost paralyzed. this is life-threatening. you might need a respirator to breathe. symptoms usually worsen over a period of weeks and then stabilize. guillain-barre can be hard to diagnose. possible tests include nerve tests and a spinal tap. most people recover. recovery can take a few weeks to a few years. treatment can help symptoms, and may include medicines or a procedure called plasma exchange. nih: national institute of neurological disorders and stroke

CDC:2 Group B Streptococcus (group B strep) is a type of bacteria that causes illness in people of all ages. Also known as GBS, group B strep disease is the most common cause of severe infections in newborns that can be deadly, but it can be prevented.

NINDS:46 Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barr

Genetics Home Reference:23 Guillain-Barré syndrome is an autoimmune disorder that affects the nerves. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In Guillain-Barré syndrome, the immune response damages peripheral nerves, which are the nerves that connect the central nervous system (the brain and spinal cord) to the limbs and organs. Specifically, the immune response affects a particular part of peripheral nerves called axons, which are the extensions of nerve cells (neurons) that transmit nerve impulses. Guillain-Barré syndrome can affect the neurons that control muscle movement (motor neurons); the neurons that transmit sensory signals such as pain, temperature, and touch (sensory neurons); or both. As a result, affected individuals can experience muscle weakness or lose the ability to feel certain sensations.

Wikipedia:68 Guillain–Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging... more...

Related Diseases for Guillain-Barre Syndrome

About this section

Diseases related to Guillain-Barre Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 205)
idRelated DiseaseScoreTop Affiliating Genes
1neuropathy, inflammatory demyelinating33.4MPZ, PMP22
2demyelinating polyneuropathy30.4MPZ, PMP22
3membranous glomerulonephritis29.7CD40LG, TNF, TNFRSF1A, TNFRSF1B
4systemic lupus erythematosus28.6CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1B
5pharyngeal-cervical-brachial variant of guillain-barré syndrome12.4
6paraparetic variant of guillain-barré syndrome12.3
7miller fisher syndrome11.8
8congenital symblepharon10.8MPZ, PMP22
9chronic inflammatory demyelinating polyneuropathy10.8
10prolymphocytic leukemia10.8MPZ, PMP22
11charcot-marie-tooth neuropathy type 2a10.8MPZ, PMP22
12pustulosis of palm and sole10.8TNF, TNFRSF1B
13cerebral sarcoidosis10.8TNF, TNFRSF1B
14dysautonomia10.7
15acneiform dermatitis10.7TNF, TNFRSF1B
16gonococcal bursitis10.7TNF, TNFRSF1B
17multiple sclerosis 510.7TNF, TNFRSF1A
18anal colloid adenocarcinoma10.7MPZ, PMP22
19autonomic dysfunction10.7
20neuropathy, recurrent, with pressure palsies10.7MPZ, PMP22
21central nervous system origin vertigo10.7MPZ, PMP22
22congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome10.6HLA-DRB1, TNF
23brain stem glioma10.6PMP22, TNF, TNFRSF1B
24microsomia hemifacial radial defects10.6HLA-DRB1, TNF
25androgen insensitivity syndrome, mild10.5HLA-DRB1, TNF
26lujo hemorrhagic fever10.5HLA-DRB1, TNF
27autonomic peripheral neuropathy10.5MPZ, PMP22, TNF
28allergic cutaneous vasculitis10.5PMP22, TNFRSF1A, TNFRSF1B
29telangiectasis10.5TNF, TNFRSF1A, TNFRSF1B
30rhizomelic dysplasia patterson lowry type10.5HLA-DRB1, TNF
31precursor b lymphoblastic lymphoma/leukemia10.5TNF, TNFRSF1A, TNFRSF1B
32sheehan syndrome10.5PMP22, TNFRSF1A, TNFRSF1B
33tibial nerve palsy10.5PMP22, TNFRSF1A, TNFRSF1B
34pyosalpinx10.5TNF, TNFRSF1A, TNFRSF1B
35rhabdoid cancer10.5TNFRSF1A, TNFRSF1B
36lichen planus pemphigoides10.5HLA-DQB1, HLA-DRB1
37heavy chain deposition disease10.5HLA-DQB1, HLA-DRB1
38erdheim-chester disease10.4CD40LG, TNF
39idiopathic juxtafoveal retinal telangiectasia10.4HLA-DQB1, HLA-DRB1
40collagenous colitis10.4HLA-DRB1, TNF
41cutaneous leishmaniasis10.4HP, TNF, TNFRSF1B
42lichtenstein syndrome10.4HLA-DQB1, HLA-DRB1
43red cell phospholipid defect with hemolysis10.4HLA-DQB1, HLA-DRB1
44sjogren's syndrome10.4CD40LG, TNF
45neuritis10.4CD40LG, PMP22
46psoriasis10.4HLA-DQB1, HLA-DRB1
47influenza10.4
48idiopathic inflammatory myopathy10.4HCRT, HLA-DQB1
49brucella melitensis brucellosis10.4CD40LG, TNF
50actinomycosis10.4HLA-DQB1, HLA-DRB1

Comorbidity relations with Guillain-Barre Syndrome via Phenotypic Disease Network (PDN):


Hypertension, EssentialRespiratory Failure
Acute Cystitis

Graphical network of the top 20 diseases related to Guillain-Barre Syndrome:



Diseases related to guillain-barre syndrome

Symptoms for Guillain-Barre Syndrome

About this section

UMLS symptoms related to Guillain-Barre Syndrome:


neuralgia, ophthalmoplegia, cerebellar ataxia, sleeplessness, vertigo/dizziness, muscle weakness, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, back pain

Drugs & Therapeutics for Guillain-Barre Syndrome

About this section

Drugs for Guillain-Barre Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1VaccinesPhase 4, Phase 36085
2ImmunoglobulinsPhase 3, Phase 24477
3AntibodiesPhase 3, Phase 24477
4Immunologic FactorsPhase 318483
5
DalfampridineapprovedPhase 262504-24-51727
Synonyms:
.gamma.-Aminopyridine
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 AP
4 Aminopyridine
4 Aminopyridine Sustained Release
4-AP
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-Pyridinamine
4-Pyridylamine
4-aminopyridine
5-22-09-00106 (Beilstein Handbook Reference)
504-24-5
A 0152
A0414
A78403_ALDRICH
AB1004971
AC-907/25014071
AC1L1C3R
AC1Q52BM
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
BRN 0105782
BSPBio_001562
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
C13728
C5H6N2
CHEBI:34385
CHEMBL284348
CID1727
Caswell No. 038
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
FT-0083754
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine SR
Fampridine [USAN:INN]
Fampridine-PR
Fampridine-SR
Fampridinum
Fampyra
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
 
KBio1_000572
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
LS-130202
Lopac-A-0152
Lopac0_000032
MLS000069400
Mi-W-3
MolPort-000-146-022
N07XX07
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
NINDS_000572
NSC 15041
NSC15041
Neurelan
Neurelan (TN)
P-Aminopyridine
PYRIDINE,4-AMINO
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
SPECTRUM1501130
STK298717
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
Spectrum_000155
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 10-3
VMI 103
VMI-10-3
VMI-103
VMI103
WLN: T6NJ DZ
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
gamma-Aminopyridine
nchem.892-comp4
p-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
pyridin-4-amine
pyridin-4-ylamine
6Rho(D) Immune GlobulinPhase 2206
7Potassium Channel BlockersPhase 2151
8Immunoglobulins, IntravenousPhase 2211
9Pharmaceutical SolutionsPhase 27004
10Complement System ProteinsPhase 2190
11
Thiamineapproved, nutraceutical8859-43-81130
Synonyms:
100660-17-1
115461-66-0
1sbr
2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol
2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydrox yethyl)-4-methylthiazolium chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethylthiazolium chloride, monohydrochloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride
3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride monohydrochloride
3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM
3-(4-AMINO-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium
3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride
3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride hydrochloride
3[(4-Amino-2-methyl-5-pyrimidinyl)-methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride
55463-15-5
57777-32-9
59-43-8
67-03-8
AC-11683
AC1L1ASK
AC1L1LOC
AC1LAODT
AC1Q4V9Q
AI3-18993
AKOS000668650
AR-1L8201
Aneurin
Aneurine
Antiberiberi factor
Apatate drape
Apate drops
B-Amin
BAS 00266240
BPBio1_000686
BSPBio_000622
Beatine
Bedome
Begiolan
Beivon
Benerva
Bequin
Berin
Betabion
Betalin S
Betaxin
Bethiamin
Bethiazine
Beuion
Bevitex
Bevitine
Bewon
Biamine
Bithiamin
Biuno
Bivatin
Bivita
C00378
C12H17N4OS
CCRIS 1906
CCRIS 5823
CHEBI:18385
CHEBI:33283
CHEBI:49105
CHEMBL1547
CHEMBL1588
CID1130
CID517305
CID6042
Cernevit-12
Chloride-hydrochloride salt of thiamine
Clotiamina
D08580
DB00152
EINECS 200-425-3
EINECS 200-641-8
Eskapen
Eskaphen
FEMA No. 3322
HSDB 220
 
Hybee
I14-14339
LS-3226
LT00233141
Lixa-beta
MLS001304099
Metabolin
MolPort-000-722-048
MolPort-001-920-086
MolPort-002-052-059
NChemBio.2007.13-comp10
NSC 36226
NSC36226
Oryzanin
Oryzanine
Prestwick0_000631
Prestwick1_000631
Prestwick2_000631
Prestwick3_000631
SBB058094
SMP1_000084
SMR000718788
SPBio_002841
ST095175
Slowten
THD
THIAMIN, VITAMIN B1
Thiadoxine
Thiamin
Thiamin dichloride
Thiaminal
Thiamine
Thiamine (INN)
Thiamine HCL
Thiamine Hydrochloride
Thiamine [INN:BAN]
Thiamine chloride
Thiamine chloride hydrochloride
Thiamine dichloride
Thiamine hydrochloride [JAN]
Thiamine monochloride
Thiamine monohydrochloride
Thiamine, chloride
Thiamine, chloride, hydrochloride
Thiamine, monohydrochloride
Thiaminium
Thiaminium chloride hydrochloride
Thiaminum
Thiaminum [INN-Latin]
Thiamol
Thiavit
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethyl, chloride, monohydrochloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride (1:1)
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-, chloride, monohydrochloride
Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-chloride
Tiamidon
Tiamina
Tiamina [INN-Spanish]
Tiaminal
TimTec1_000613
Trophite
UNII-X66NSO3N35
VIB
Vetalin S
Vinothiam
Vitamin B1
Vitamin B1 (TN)
Vitamin B1 hydrochloride (VAN)
Vitaneurin
Vitaneuron
ZINC00049153
[5-[[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]methyl]-2-methylpyrimidin-4-yl]azanium dichloride
bmse000274
nchembio.121-comp5
thiamin
thiamine
thiamine(1+)
thiamine(1+) ion
thiaminium
vitamin B1
vitamin b1(thiamine)
12Chelating Agents667
13Anticoagulants1760
14Calcium, Dietary4678
15Vitamins3857
16Vitamin B Complex2847
17Immunoglobulin G146
18Autoantibodies117
19
Citric Acidnutraceutical100177-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
20CitrateNutraceutical1001
21ThiaminNutraceutical88

Interventional clinical trials:

(show all 31)
idNameStatusNCT IDPhase
1Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of AgeCompletedNCT01985997Phase 4
2Efficacy and Safety Study of GB-0998 for Guillain-Barré SyndromeCompletedNCT02342184Phase 3
3Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801CompletedNCT01604746Phase 3
4Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré SyndromeRecruitingNCT02221271Phase 3
5Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary VaccinationActive, not recruitingNCT01777308Phase 3
6Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primaActive, not recruitingNCT01934140Phase 3
7Early Mechanical Ventilation for Guillain Barré SyndromeCompletedNCT00167622Phase 2
8Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridineCompletedNCT00056810Phase 2
9Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) PatientsRecruitingNCT02780570Phase 2
10Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome StudyRecruitingNCT02029378Phase 2
11JET-GBS - Japanese Eculizumab Trial for GBSActive, not recruitingNCT02493725Phase 2
12Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS)CompletedNCT01306578
13Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome.CompletedNCT01024088
14Brain Computer Interface for Communication in ICU: a Feasibility StudyCompletedNCT01005524
15Regional Citrate Anticoagulation in Plasma Exchange TreatmentCompletedNCT01370200
16Cervarix Long-term Safety SurveillanceCompletedNCT01498627
17Surveillance for Adverse Events Following Pandemic H1N1 ImmunizationCompletedNCT01289418
18Surveillance for Adverse Events Following Influenza ImmunizationCompletedNCT01318876
19Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United KingdomCompletedNCT01953822
20International Guillain-Barré Syndrome Outcome StudyRecruitingNCT01582763
21sCD163 as a Potential Biomarker in Guillain- Barré SyndromeRecruitingNCT02582853
22The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin InnervationRecruitingNCT00173199
23Thiamin (Vitamin B1) Levels in Eating Disorder Adolescent PatientsRecruitingNCT02164487
24Safety Study of GBS Following Menactra Meningococcal VaccinationActive, not recruitingNCT00575653
25Change of Nerve Conduction Properties in IVIg Dependent NeuropathiesActive, not recruitingNCT01655394
26Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling by invitationNCT02422875
27Processing Integration in Neurological Patients Using fMRINot yet recruitingNCT02722070
28Perception and Multisensory Integration in Neurological Patients Using fMRINot yet recruitingNCT01469858
29Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions.Not yet recruitingNCT01516385
30Gastrointestinal Transit Time in Patients With Guillain-Barré SyndromeSuspendedNCT02459808
31Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre SyndromeTerminatedNCT00004833

Search NIH Clinical Center for Guillain-Barre Syndrome

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: guillain-barre syndrome

Genetic Tests for Guillain-Barre Syndrome

About this section

Anatomical Context for Guillain-Barre Syndrome

About this section

MalaCards organs/tissues related to Guillain-Barre Syndrome:

33
Brain, Spinal cord, Testes, Heart, Liver, T cells, Lung

Animal Models for Guillain-Barre Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Guillain-Barre Syndrome:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053898.0CD40LG, HLA-DQB1, MBP, MPZ, PMP22, TNF
2MP:00053697.8HCRT, HLA-DQB1, PMP22, TNF, TNFRSF1A, TNFRSF1B
3MP:00053847.2CD40LG, HLA-DQB1, HP, MBP, MPZ, PMP22
4MP:00036317.1CD40LG, HCRT, HLA-DQB1, MBP, MPZ, PMP22
5MP:00053976.6CD40LG, HLA-DQA1, HLA-DQB1, HP, MBP, MPZ
6MP:00053876.3CD40LG, HLA-DQA1, HLA-DQB1, HP, MBP, MPZ

Publications for Guillain-Barre Syndrome

About this section

Articles related to Guillain-Barre Syndrome:

(show top 50)    (show all 157)
idTitleAuthorsYear
1
Bilateral Ptosis as the First Presentation of Guillain-Barre Syndrome. (27057192)
2016
2
Similarities of serum anti-ganglioside antibodies in first and third episodes of recurrent Guillain-Barre syndrome: case report. (25845761)
2015
3
Guillain-Barre Syndrome: Clinical Presentation, Treatment Pattern And Outcome. (26533694)
2015
4
Reversible cardiomyopathy in Guillain Barre syndrome. (25856949)
2014
5
Guillain-Barre syndrome associated with preceding hepatitis E virus infection. (24415572)
2014
6
An unusual case of Guillain-Barre syndrome following toxic shock syndrome in a burned child. (24182693)
2013
7
Epidemiological aspects of Guillain-Barre syndrome. (23821025)
2013
8
Guillain-Barre syndrome in Asia. (24357682)
2013
9
Guillain-Barre syndrome following spinal anaesthesia. (23763810)
2013
10
Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. (24013368)
2013
11
A case report of overlapping Bickerstaff brainstem encephalitis and Guillain-Barre syndrome. (24463996)
2013
12
Guillain-Barre syndrome-like illness in association with electrical shock injury. (24136915)
2013
13
Genome Sequences of the Guillain-Barre Syndrome Outbreak-Associated Campylobacter jejuni Strains ICDCCJ07002 and ICDCCJ07004. (23704181)
2013
14
Postinfectious Guillain-Barre syndrome in a patient with methimazole-induced agranulocytosis. (24307850)
2013
15
Guillain Barre syndrome as a manifestation of neurological melioidosis. (24339608)
2013
16
Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome. (24378177)
2013
17
Acute hepatitis E complicated by Guillain-Barre syndrome in Portugal, December 2012--a case report. (23987830)
2013
18
A multicentre prospective study of Guillain-Barre Syndrome in Japan: a focus on the incidence of subtypes. (24273220)
2013
19
Clinically silent posterior reversible encephalopathy in Guillain-Barre syndrome. (23573560)
2013
20
Influenza vaccines and guillain-barre syndrome: the continuing question. (24166961)
2013
21
An unusual case of recurrent guillain-barre syndrome of a different subtype five years after initial diagnosis. (23710387)
2013
22
Hepatitis E and Guillain-Barre syndrome. (23899686)
2013
23
Increased Guillain-Barre syndrome admissions in Shiraz, southern Iran. (24250891)
2013
24
Outcome and its predictors in Guillain-Barre syndrome. (22566597)
2012
25
Heterotopic ossification of the hips in a patient with Guillain Barre syndrome demonstrated on SPECT/CT. (22899193)
2012
26
Invited commentary: Influenza vaccine and Guillain-Barre syndrome--is there a risk? (22582208)
2012
27
Guillain-Barre syndrome after coronary artery bypass surgery. (22899666)
2012
28
Contamination with gangliosides in brain-derived rabies vaccine may trigger Guillain--Barre syndrome. (21949103)
2012
29
Guillain-Barre syndrome in colorectal cancer. (22524581)
2012
30
TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome. (21482924)
2011
31
Recognizing Guillain-Barre syndrome in preschool children. (21357832)
2011
32
High incidence of Guillain-Barre syndrome in children, Bangladesh. (21762603)
2011
33
Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. (21652600)
2011
34
Keeping it simple: is there a need for the various subtyping of axonal forms of Guillain-Barre syndrome? (21551171)
2011
35
Genomic characterization of the Guillain-Barre syndrome-associated Campylobacter jejuni ICDCCJ07001 Isolate. (21124772)
2010
36
This disorder has some nerve: chronic pain in Guillain-Barre syndrome. (20861453)
2010
37
Investigation of suspected Guillain-Barre syndrome in childhood: What is the role for gadolinium enhanced magnetic resonance imaging of the spine? (20626577)
2010
38
Magnetic resonance imaging of childhood Guillain-Barre syndrome. (20556395)
2010
39
Celiac disease associated with recurrent Guillain Barre syndrome. (21048269)
2010
40
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. (16170091)
2005
41
Guillain-Barre syndrome with meningoencephalitis after Campylobacter jejuni infection. (15602203)
2004
42
Bickerstaff's brainstem encephalitis, Miller Fisher syndrome and Guillain-Barre syndrome overlap with negative anti-GQ1b antibodies. (12603297)
2003
43
Severe cardiovascular autonomic dysfunction in a patient with Guillain-Barre syndrome: a case report. (11269930)
2000
44
HLA alleles in patients with Guillain-Barre syndrome. (11776098)
2000
45
Ataxic form of Guillain-Barr syndrome associated with anti-GD1b IgG antibody. (10864627)
2000
46
Guillain-Barre syndrome following 2-chlorodeoxyadenosine treatment for Hairy Cell Leukemia. (11342351)
2000
47
A neurophysiological study in children with Miller Fisher syndrome and Guillain-Barre syndrome. (9134191)
1997
48
Dysautonomia in Guillain Barre syndrome. (3654548)
1987
49
Laseque's sign--an important bedside diagnostic sign in acute polyradiculopathy (Guillain-Barre syndrome). (451640)
1979
50
GUILLAIN-BARRE SYNDROME ASSOCIATED WITH ULCEROGLANDULAR TULAREMIA. (14215606)
1964

Variations for Guillain-Barre Syndrome

About this section

Expression for genes affiliated with Guillain-Barre Syndrome

About this section
Search GEO for disease gene expression data for Guillain-Barre Syndrome.

Pathways for genes affiliated with Guillain-Barre Syndrome

About this section

Pathways related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 29)
idSuper pathwaysScoreTop Affiliating Genes
19.7TNF, TNFRSF1A
29.6MBP, MPZ, PMP22
39.4CD40LG, TNF, TNFRSF1A
49.4CD40LG, TNFRSF1A, TNFRSF1B
5
Show member pathways
9.4TNF, TNFRSF1A, TNFRSF1B
6
Show member pathways
9.4TNF, TNFRSF1A, TNFRSF1B
79.4TNF, TNFRSF1A, TNFRSF1B
89.4TNF, TNFRSF1A, TNFRSF1B
99.4TNF, TNFRSF1A, TNFRSF1B
10
Show member pathways
9.4TNF, TNFRSF1A, TNFRSF1B
11
Show member pathways
9.4TNF, TNFRSF1A, TNFRSF1B
129.4TNF, TNFRSF1A, TNFRSF1B
13
Show member pathways
9.1CD40LG, TNF, TNFRSF1A, TNFRSF1B
14
Show member pathways
9.1CD40LG, TNF, TNFRSF1A, TNFRSF1B
15
Show member pathways
9.1CD40LG, TNF, TNFRSF1A, TNFRSF1B
16
Show member pathways
9.1CD40LG, TNF, TNFRSF1A, TNFRSF1B
178.5HLA-DQA1, HLA-DQB1, HLA-DRB1
188.5HLA-DQA1, HLA-DQB1, HLA-DRB1
19
Show member pathways
8.5HLA-DQA1, HLA-DQB1, HLA-DRB1
208.5HLA-DQA1, HLA-DQB1, HLA-DRB1
21
Show member pathways
8.2CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1
228.2HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF
238.0CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, MPZ
24
Show member pathways
7.8HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
257.8HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
267.8HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
27
Show member pathways
7.7CD40LG, HLA-DQA1, HLA-DQB1, TNF, TNFRSF1A, TNFRSF1B
28
Show member pathways
7.5CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A
29
Show member pathways
7.1CD40LG, HLA-DQA1, HLA-DQB1, HLA-DRB1, TNF, TNFRSF1A

GO Terms for genes affiliated with Guillain-Barre Syndrome

About this section

Cellular components related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class II protein complexGO:00426139.5HLA-DQA1, HLA-DQB1
2integral component of lumenal side of endoplasmic reticulum membraneGO:00715569.3HLA-DQA1, HLA-DQB1
3trans-Golgi network membraneGO:00325888.5HLA-DQA1, HLA-DQB1, HLA-DRB1
4ER to Golgi transport vesicle membraneGO:00125078.2HLA-DQA1, HLA-DQB1, HLA-DRB1

Biological processes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1regulation of immunoglobulin secretionGO:005102310.4CD40LG, TNF
2regulation of establishment of endothelial barrierGO:190314010.2TNF, TNFRSF1A
3death-inducing signaling complex assemblyGO:007155010.1TNF, TNFRSF1A
4positive regulation of ceramide biosynthetic processGO:200030410.0TNF, TNFRSF1A
5antigen processing and presentation of peptide or polysaccharide antigen via MHC class IIGO:00025049.9HLA-DQA1, HLA-DRB1
6immunoglobulin production involved in immunoglobulin mediated immune responseGO:00023819.7HLA-DQB1, HLA-DRB1
7establishment of protein localization to plasma membraneGO:00900029.6TNF, TNFRSF1A
8extrinsic apoptotic signaling pathway via death domain receptorsGO:00086259.4TNF, TNFRSF1A
9intrinsic apoptotic signaling pathway in response to DNA damageGO:00086309.4TNF, TNFRSF1A, TNFRSF1B
10regulation of cell proliferationGO:00421279.4TNF, TNFRSF1A, TNFRSF1B
11antigen processing and presentationGO:00198828.8HLA-DQA1, HLA-DQB1, HLA-DRB1

Sources for Guillain-Barre Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet